STI

This information sheet discusses the link between STDs and HIV. It explains how individuals with STDS have an increased susceptibility to HIV and individuals with HIV have increased infectiousness. The information sheet discusses how STD treatment can slow the spread of HIV and the implications for HIV and STD prevention programs. Information is provided for accessing the services of national health organizations.

This monograph is a curricular outline for examination of an STD patient. It explains the rationale and general clinical approach including epidemiological and medical goals of an STD intervention, taking a sexual history, risk indicators for STD, chief complaint and history of present illness, past medical and STD history, gynecologic history, HIV risk assessment, social history, clinical management, and patient education.

This report summarizes laboratory and epidemiologic findings associated with reduced susceptibility to azithromycin. It notes that in August-October 2009, five of 55 N. gonorrhoeae isolates obtained from men with symptomatic urethritis tested at San Diego County’s main municipal STD clinic had high azithromycin minimum inhibitory concentrations (MIC)s.

This report discusses the sexually transmitted disease (STD), chlamydia, which is common among sexually active adolescents and young adults. It explains that although chlamydia may be asymptomatic, it can have serious consequences in females, including infertility; hence, the importance of chlamydia prevention. Screening females aged <25 years is ranked by the National Commission on Prevention Priorities as one of the 10 most beneficial and cost-effective prevention services, but it also is one of the most underutilized.

This report describes tests of an analysis of data from five laboratories that used reverse sequence screening during 2006-2010 to identify persons with possible untreated syphilis. Three sites served patient populations with low prevalence of syphilis, and two sites served patient population with high prevalence. The results indicated that among sera reactive on initial screening with an automatable treponemal enzyme and chemiluminescence immunoassays (EIA/CIA), 56.7 percent had a nonreactive rapid plasma regain (RPR) test.

This pamphlet provides information about the STD chlamydia. It lists basic facts about the disease and discusses transmission, symptoms for men and women, testing, and treatment. The pamphlet explains that recent sex partners should be notified, as they would need to be tested for the disease and treated if infected. Chlamydia can be cured with antibiotic treatment, but an individual can be reinfected.

This pamphlet provides information about genital human papillomavirus (HPV). It notes that this is the most common sexually transmitted virus in the US and that most people who have the disease do not know it, as they may not have symptoms. It explains how the disease is transmitted, the symptoms and health effects of HPV, and focuses on important knowledge about HPV for both men and women. Women are warned that some types of HPV can cause cervical cancer in women, but that a woman can protect herself by getting regular Pap tests and early treatment for problems that could turn into cancer.

This report summarizes trends in cephalosporin susceptibility among N. gonorrhoeae isolates in the United States during 2000--2010 using data from the Gonococcal Isolate Surveillance Project (GISP). During that period, the percentage of isolates with elevated minimum inhibitory concentrations (MICs) to cephalosporins (=0.25 µg/mL for cefixime and =0.125 µg/mL for ceftriaxone) increased from 0.2% in 2000 to 1.4% in 2010 for cefixime and from 0.1% in 2000 to 0.3% in 2010 for ceftriaxone.

On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck & Co. Inc.) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series; males aged 22 through 26 years may be vaccinated. These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males aged 9 through 26 years.

This pamphlet provides the general public with information on genital warts. The pamphlet discusses various types of warts, transmission, symptoms, medical treatment, and the relationship of warts to cancer. Contact information is provided for sexual health services in Australia.